IWC
NGEN

Integrated Wealth Concepts’s NervGen Pharma NGEN Stock Holding History

Integrated Wealth Concepts’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Sell
74,215
-12,600
-15% -$39.1K ﹤0.01% 2502
2026
Q1 		$327K Buy
+86,815
New +$376K ﹤0.01% 1799

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Integrated Wealth Concepts's NGEN Position: Q2 2026 in Review

Integrated Wealth Concepts reduced its NervGen Pharma (NGEN) stake by 15% in Q2 2026, selling an estimated $39.1K and leaving 74,215 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #2502.

Integrated Wealth Concepts first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $327K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Integrated Wealth Concepts held 74,215 shares of NervGen Pharma worth $153K as of Q2 2026.
  • Integrated Wealth Concepts sold 12,600 NervGen Pharma shares in Q2 2026, an estimated $39.1K.
  • NervGen Pharma made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #2502 holding.
  • Integrated Wealth Concepts first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Integrated Wealth Concepts's NervGen Pharma position peaked at $327K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.